Clinical Cancer Research, Vol 2, Issue 11 1851-1857, Copyright © 1996 by American Association for Cancer Research

ARTICLES

Effects of anti-erbB-2 (HER-2/neu) recombinant oncotoxin AR209 on human non-small cell lung carcinoma grown orthotopically in athymic nude mice

N Skrepnik, JC Araya, Z Qian, H Xu, J Hamide, R Mera and JD Hunt
Departments of Biochemistry and Molecular Biology, Pathology, and Radiology, New Orleans, Louisiana 70112, USA.

The recombinant oncotoxin AR209 [e23(Fv)PE38KDEL; formerly OLX-209] was developed to treat neoplasia that expresses the c-erbB-2 (HER-2/neu) protein product p185(erbB-2). The AR209 compound contains a single-chain antibody domain specific for p185(erbB-2), coupled with a portion of the Pseudomonas exotoxin. The drug has been shown to be effective in inhibiting cells that overexpress erbB-2 due to gene amplification and in cells that do not contain amplified erbB-2 but express slightly higher levels of the protein than normal cells do. To test the efficacy of AR209 on human lung tumors, athymic nude mice were inoculated intrathoracically with a cell line derived from a poorly differentiated lung adenocarcinoma. This cell line, termed 201T, expresses moderately elevated levels of p185(erbB-2) 7.6-fold over normal bronchial epithelium. Mice treated with i.v. injections of AR209 for 5 weeks after orthotopic tumor implantation had smaller tumors and in 20% of cases showed no evidence of disease. The data from this study indicate that AR209 may be an effective treatment for patients with non-small cell lung cancers that express p185(erbB-2).

This article has been cited by other articles:

				Y. Su, J. Ortiz, S. Liu, T. H. Bugge, R. Singh, S. H. Leppla, and A. E. Frankel Systematic Urokinase-Activated Anthrax Toxin Therapy Produces Regressions of Subcutaneous Human Non-Small Cell Lung Tumor in Athymic Nude Mice Cancer Res., April 1, 2007; 67(7): 3329 - 3336. [Abstract] [Full Text] [PDF]

				C. J. Langer, P. Stephenson, A. Thor, M. Vangel, and D. H. Johnson Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598 J. Clin. Oncol., April 1, 2004; 22(7): 1180 - 1187. [Abstract] [Full Text] [PDF]

				M. Keir, R. Fiddes, J. C. Biggs, and P. P. Kearney Sensitivity of c-erbB Positive Cells to a Ligand Toxin and Its Utility in Purging Breast Cancer Cells from Peripheral Blood Stem Cell (PBSC) Collections Stem Cells, November 1, 2000; 18(6): 422 - 427. [Abstract] [Full Text]